Drug intelligence / Profile preview

CS-TATI-1

Development stage: Preclinical
Lead developer: Cannabis Science
Modality: Small Molecules

Overview

CS-TATI-1 is a small molecule drug under development by Cannabis Science for the treatment of HIV infections and Kaposi Sarcoma. Its mechanism of action involves acting as a cannabinoid receptor agonist and an inhibitor of the HIV Tat gene product, which is critical for viral replication. The drug aims to reduce inflammation associated with HIV infection and inhibit viral replication, potentially improving health outcomes in patients with HIV/AIDS, especially those with drug-resistant strains or intolerance to current therapies. Preclinical studies are ongoing in the United States[2][3][5].

Other names: CS TATI 1

Targets

Tat (HIV-1 Tat)CB (Cannabinoid receptors)

Beyond the preview

Go deeper on CS-TATI-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-TATI-1.

Explore the full profile